Long COVID, Post-Acute COVID19 Syndrome, Post-COVID19 Condition
Conditions
Keywords
long covid, PASC, post COVID condition, cognition, brain fog, amantadine
Brief summary
This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.
Detailed description
This study will enroll 60 subjects with Long COVID and cognitive symptoms such as problems with memory, concentration, speech and attention, and "brain fog." Subjects will be assigned randomly to two groups. One group will be treated with amantadine, the other group will receive placebo. The study will last 4 months. During that time, subjects will be assessed at regular intervals with symptom questionnaires, cognitive tests, and lab measurements.
Interventions
DRUGAmantadine
Subjects will be give amantadine 100 mg twice daily.
Sponsors
Ohio State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Pilot randomized clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years of age and above at the signing of informed consent 2. Had a positive laboratory or home test for COVID19 within one year prior to signing of informed consent, with subsequent symptoms meeting criteria for PASC. 3. Subjective Cognitive impairment associated with PASC 4. Cognitive symptoms will be formally assessed at a pre-enrollment visit using the PROMIS Cognitive Function Questionnaire (CGQ) and the PROMIS Cognitive Abilities subset (CAS), which are validated patient-reported measures of subjective cognitive functioning. Potential participants must have a cumulative score less than 60 (indicating at least mild subjective cognitive dysfunction) to be eligible. 5. Is willing and able to comply with study visits and study-related procedures/assessments. 6. Is able to provide informed consent to participate in the study 5. 7. Is not currently taking a medication with adverse interactions with amantadine. (Table 2) 8. If the participant is of child bearing potential, , is not pregnant at enrollment based on negative urine pregnancy test. 9. If the participant is of child-bearing potential, is consistently using one or more forms of prescribed birth control, such as an oral contraceptive, intrauterine device or a long-acting reversible contraceptive. 10. Is not breastfeeding. 11. Is willing to abstain from alcohol use for the duration of the study. 12. Endorses self-reported cognitive impairment on the PROMIS CF\[40\]. 13. Does not have any other contraindications to amantadine use as noted in section 6 below or as identified by the study clinician investigators.
Exclusion criteria
1. At risk for complications of study drug with conditions such as: * Lifetime history of compulsive or impulsive behavior: Compulsive gambling, hypersexuality, binge eating; suicidality. * Underweight, malnourished at time of enrollment. * History of restrictive eating disorder within 3 months prior to consent. * Lifetime history of heart failure or diagnosed cardiac arrhythmia. * Untreated angle closure glaucoma at time of enrollment. * Lifetime history of psychosis or psychotic disorder. * Lifetime history of seizure disorder. * Known allergy to amantadine. * History of binge drinking, heavy alcohol use, or alcohol use disorder as defined by the National Institute on Alcohol Abuse and Alcoholism (NIAAA)\[54\] and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)\[55\]. * Use of kava-kava within 3 months prior to consent. * Breastfeeding at screening or expected to be breastfeeding during study period. * Pregnant at time of screening or expecting to become pregnant during the study period. 2. Is taking a medication that adversely interacts with amantadine (see Table 2) 3. Has any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study. 4. Prior diagnosis of dementia, neurodegenerative disorder, multiple sclerosis or other autoimmune neurologic disorder, or cognitive impairment. 5. Enrolled in any other research study involving intervention for PASC. 6. If the individual is of child-bearing potential, is not consistently using one or more forms of prescribed birth control. 7. Is not willing to abstain from alcohol for the duration of the study. 8. Is not willing and able to adhere to study visits and study-related procedures/assessments. 9. Is not able to provide informed consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement in cognitive symptoms | 4 months | Improvement in scores on self-assessment of overall cognitive functioning |
| Improvement on objective cognitive testing | 4 months | Subjects will be administered battery of cognitive tests to determine if there is a change in objective cognitive function |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mood symptoms | 4 months | Subjects will be administered anxiety and depression questionnaires to determine if there is improvement in mood symptoms. |
| Medication tolerability | 4 months | Subjects will complete a questionnaire addressing tolerability of amantadine and side effects experienced |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAndrew I Schamess, MD
Ohio State University
Outcome results
None listed